Evidence mapPaperPMID 38635981Full record

ArticleJournal of medical Internet research2024

The Alzheimer's Knowledge Base: A Knowledge Graph for Alzheimer Disease Research.

Joseph D Romano, Van Truong, Rachit Kumar, Mythreye Venkatesan, Britney E Graham, Yun Hao, Nick Matsumoto, Xi Li, Zhiping Wang, Marylyn D Ritchie and 2 more

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. A random-walk-based learning framework to uncover novel gene candidates for Alzheimer's disease therapy.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2026
    Article
  7. Article
  8. Article
  9. A Survey on Unifying Large Language Models and Knowledge Graphs for Biomedicine and Healthcare.KDD : proceedings. International Conference on Knowledge Discovery & Data Mining · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Joseph D RomanoInstitute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-7999-4399
Van TruongInstitute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-5485-1818
Rachit KumarInstitute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-7736-3307
Mythreye VenkatesanDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.ORCID 0000-0001-9946-0688
Britney E GrahamDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.ORCID 0000-0002-5417-3957
Yun HaoInstitute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0009-0004-6198-3060
Nick MatsumotoDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.ORCID 0000-0002-3280-9678
Xi LiDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.ORCID 0009-0006-4205-0729
Zhiping WangDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.ORCID 0000-0002-3796-3164
Marylyn D RitchieInstitute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-1208-1720
Li ShenInstitute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-5443-0503
Jason H MooreDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.ORCID 0000-0002-5015-1099

Funding

Translational Research Support CoreP30ES013508 · UNIVERSITY OF PENNSYLVANIA · 2025 to 2025
$1.6M
Artificial Intelligence Strategies for Alzheimer's Disease ResearchU01AG066833 · CEDARS-SINAI MEDICAL CENTER · 2025 to 2025
$1.6M
Discovering clinical endpoints of toxicity via graph machine learning and semantic data analysisR00LM013646 · NLM · UNIVERSITY OF PENNSYLVANIA · 2024 to 2025
$479k
NIA NIH HHS R01 AG066833NIA NIH HHS U01 AG066833NIEHS NIH HHS P30 ES013508NLM NIH HHS R00 LM013646NLM NIH HHS R01 LM010098NLM NIH HHS R01 LM013463
6 · The paper itself

Abstract

backgroundAs global populations age and become susceptible to neurodegenerative illnesses, new therapies for Alzheimer disease (AD) are urgently needed. Existing data resources for drug discovery and repurposing fail to capture relationships central to the disease's etiology and response to drugs.

objectiveWe designed the Alzheimer's Knowledge Base (AlzKB) to alleviate this need by providing a comprehensive knowledge representation of AD etiology and candidate therapeutics.

methodsWe designed the AlzKB as a large, heterogeneous graph knowledge base assembled using 22 diverse external data sources describing biological and pharmaceutical entities at different levels of organization (eg, chemicals, genes, anatomy, and diseases). AlzKB uses a Web Ontology Language 2 ontology to enforce semantic consistency and allow for ontological inference. We provide a public version of AlzKB and allow users to run and modify local versions of the knowledge base.

resultsAlzKB is freely available on the web and currently contains 118,902 entities with 1,309,527 relationships between those entities. To demonstrate its value, we used graph data science and machine learning to (1) propose new therapeutic targets based on similarities of AD to Parkinson disease and (2) repurpose existing drugs that may treat AD. For each use case, AlzKB recovers known therapeutic associations while proposing biologically plausible new ones.

conclusionsAlzKB is a new, publicly available knowledge resource that enables researchers to discover complex translational associations for AD drug discovery. Through 2 use cases, we show that it is a valuable tool for proposing novel therapeutic hypotheses based on public biomedical knowledge.

Indexed as

Alzheimer DiseaseHumansKnowledgeKnowledge BasesMachine LearningPattern Recognition, AutomatedAlzheimerAlzheimer diseaseartificial intelligencedrug discoverydrug repurposingetiologyheterogeneous graphknowledge baseknowledge graphmachine learningopen sourcetherapeutic discoverytherapeutic targets

Identifiers

PMID38635981
PMCPMC11066745

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.